Pacira Pharmaceuticals Inc (NASDAQ:PCRX) – Piper Jaffray Companies upped their FY2018 earnings per share (EPS) estimates for shares of Pacira Pharmaceuticals in a research report issued on Monday, October 8th. Piper Jaffray Companies analyst D. Amsellem now anticipates that the company will post earnings per share of ($0.06) for the year, up from their previous forecast of ($0.08). Piper Jaffray Companies has a “Buy” rating and a $51.00 price target on the stock.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its earnings results on Thursday, August 2nd. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.37. The firm had revenue of $84.10 million during the quarter, compared to analyst estimates of $77.53 million. Pacira Pharmaceuticals had a negative net margin of 3.64% and a negative return on equity of 0.39%. The company’s quarterly revenue was up 18.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.11) earnings per share.
A number of other equities analysts have also weighed in on the stock. Royal Bank of Canada set a $55.00 target price on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, September 19th. Wedbush set a $85.00 target price on shares of Pacira Pharmaceuticals and gave the stock an “outperform” rating in a research report on Monday, August 6th. Stifel Nicolaus assumed coverage on shares of Pacira Pharmaceuticals in a research report on Thursday, September 13th. They issued a “sell” rating and a $41.00 price objective for the company. Cowen restated a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Tuesday, July 10th. Finally, ValuEngine lowered shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, September 11th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company. Pacira Pharmaceuticals presently has an average rating of “Hold” and an average target price of $48.00.
Shares of NASDAQ:PCRX opened at $44.14 on Thursday. The company has a debt-to-equity ratio of 0.98, a current ratio of 8.58 and a quick ratio of 7.79. The stock has a market cap of $2.01 billion, a price-to-earnings ratio of -77.05 and a beta of 1.86. Pacira Pharmaceuticals has a twelve month low of $26.95 and a twelve month high of $52.60.
Institutional investors have recently made changes to their positions in the business. Granahan Investment Management Inc. MA lifted its position in Pacira Pharmaceuticals by 12.3% during the second quarter. Granahan Investment Management Inc. MA now owns 188,086 shares of the company’s stock valued at $6,028,000 after purchasing an additional 20,617 shares during the last quarter. Mutual of America Capital Management LLC lifted its position in Pacira Pharmaceuticals by 15.3% during the second quarter. Mutual of America Capital Management LLC now owns 155,554 shares of the company’s stock valued at $4,986,000 after purchasing an additional 20,606 shares during the last quarter. Russell Investments Group Ltd. lifted its position in Pacira Pharmaceuticals by 14.7% during the second quarter. Russell Investments Group Ltd. now owns 56,610 shares of the company’s stock valued at $1,813,000 after purchasing an additional 7,249 shares during the last quarter. Rice Hall James & Associates LLC lifted its position in Pacira Pharmaceuticals by 3.7% during the second quarter. Rice Hall James & Associates LLC now owns 338,032 shares of the company’s stock valued at $10,834,000 after purchasing an additional 12,161 shares during the last quarter. Finally, US Bancorp DE lifted its position in Pacira Pharmaceuticals by 40.7% during the second quarter. US Bancorp DE now owns 6,038 shares of the company’s stock valued at $194,000 after purchasing an additional 1,746 shares during the last quarter.
In other Pacira Pharmaceuticals news, VP Lauren Bullaro Riker sold 1,667 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Wednesday, August 22nd. The shares were sold at an average price of $44.48, for a total transaction of $74,148.16. Following the completion of the sale, the vice president now directly owns 10,474 shares in the company, valued at $465,883.52. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Mark A. Kronenfeld bought 1,000 shares of the company’s stock in a transaction on Tuesday, August 28th. The shares were bought at an average price of $44.61 per share, with a total value of $44,610.00. Following the completion of the transaction, the director now owns 8,577 shares of the company’s stock, valued at $382,619.97. The disclosure for this purchase can be found here. Insiders sold 40,502 shares of company stock valued at $1,913,864 over the last 90 days. 5.90% of the stock is owned by company insiders.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
Read More: What is the NASDAQ Stock Market?
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.